What is the appropriate treatment for Campylobacter jejuni infection?

Treatment for Campylobacter jejuni Infection

Azithromycin is the first-line antibiotic for Campylobacter jejuni infection, given as either a single 1-gram dose or 500 mg daily for 3 days, particularly when treatment is initiated early (within 72 hours of symptom onset). 1

When to Treat

Antibiotic therapy is most beneficial when:

• Started within 72 hours of symptom onset - this is the critical window where treatment significantly reduces symptom duration from 50-93 hours to 16-30 hours 1
• Moderate to severe disease is present (incapacitating diarrhea, dysentery, or fever)
• High-risk patients: immunocompromised, extremes of age, chronic illness 2, 3

For mild, self-limited cases in immunocompetent hosts, supportive care with oral rehydration is often sufficient 4, 5.

Antibiotic Selection Algorithm

First-Line: Azithromycin

• Dosing: 1000 mg single dose (can split over first day to reduce GI side effects) OR 500 mg daily × 3 days 1
• Rationale: Superior efficacy against fluoroquinolone-resistant Campylobacter (>90% resistance rates in Southeast Asia, increasingly worldwide) 1
• Advantages: Effective for dysentery, febrile diarrhea, and invasive pathogens; minimal resistance (2-3.7%) 6, 7
• Side effects: Dose-related nausea (3%), vomiting (<1%) - exacerbated by underlying GI infection 1

Alternative: Fluoroquinolones (Geographic Considerations)

• Use only if: Non-dysenteric watery diarrhea AND low local fluoroquinolone resistance rates
• Options: Ciprofloxacin 500-750 mg single dose or × 3 days; Levofloxacin 500 mg single dose or × 3 days 1
• Major limitation: 32-62% resistance rates reported globally 6, 7
• Contraindications: Dysentery, fever, Southeast Asia/India travel, suspected invasive pathogens 1
• Risks: Achilles tendon rupture (FDA black box warning), C. difficile infection, QT prolongation, promotes gut dysbiosis and multidrug-resistant bacteria 1

Do NOT Use: Rifaximin

• Contraindicated for Campylobacter - up to 50% treatment failure rate with invasive pathogens 1
• Only appropriate for non-invasive E. coli-predominant diarrhea 1

Critical Pitfalls to Avoid

1. Delayed treatment beyond 72 hours - significantly diminishes antibiotic benefit 1

2. Empiric fluoroquinolones for dysentery or febrile diarrhea - high risk of treatment failure due to widespread Campylobacter resistance, now documented globally (not just Thailand) 1

3. Treating bloody diarrhea without considering STEC - if Shiga toxin-producing E. coli O157 is possible, avoid ALL antibiotics (fluoroquinolones, β-lactams, TMP-SMX, metronidazole) as they increase hemolytic-uremic syndrome risk 5-10 fold 2, 3

4. Continuing empiric antibiotics when symptoms worsen - reassess for alternative diagnoses or complications 1

Special Populations

Immunocompromised/Bacteremia: Azithromycin remains first-line; treatment duration may extend beyond 3 days for systemic complications 8, 5

Children: Macrolides (azithromycin, erythromycin) show excellent activity with MIC₉₀ = 0.5 mg/L and minimal resistance 7

Supportive Care

Oral rehydration is the cornerstone of management for all cases 4. Loperamide may be used for moderate symptoms but must be discontinued if dysentery develops or symptoms worsen 1.

The evidence strongly supports azithromycin as the universal first-line agent given global fluoroquinolone resistance patterns, superior efficacy in dysentery, and excellent safety profile 1.